Denali Therapeutics (DNLI)
(Delayed Data from NSDQ)
$26.83 USD
-1.17 (-4.18%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $26.81 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
DNLI 26.83 -1.17(-4.18%)
Will DNLI be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for DNLI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DNLI
Strength Seen in Voyager Therapeutics (VYGR): Can Its 17.5% Jump Turn into More Strength?
Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?
DNLI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?
Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?
Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug
Other News for DNLI
Sanofi, Denali face another mid-stage setback for neurology therapy
Denali Therapeutics (DNLI) Receives a Buy from TD Cowen
Denali Therapeutics reinstated with a Market Perform at Raymond James
Denali Therapeutics’ Oditrasertib Phase 2 Study Discontinued
Cantor Fitzgerald gets more bearish on Denali Therapeutics, downgrades shares